What is Abselion?
Founded in 2018 as HexagonFab within the University of Cambridge, Abselion has evolved into a specialized developer of protein research instrumentation. The company addresses a significant bottleneck in modern biology: the reliance on manual, time-consuming workflows for protein analysis. By leveraging its RED technology, Abselion has engineered the Amperia system, a compact and cost-effective platform designed to democratize access to high-throughput protein research. The company's market position is defined by its ability to bridge the gap between complex laboratory requirements and the need for accessible, bench-ready analytical tools, effectively serving both academic research institutions and commercial biopharmaceutical entities.
How much funding has Abselion raised?
Abselion has raised a total of $8.4M across 1 funding round:
Series A
$8.4M
Series A (2024): $8.4M with participation from Merck Ventures, the Untitled Ventures, and BGF
Key Investors in Abselion
Merck Ventures
M Ventures is the strategic, corporate venture capital arm of Merck, focusing on innovative technologies that impact core business areas through early-stage investment and company creation.
the Untitled Ventures
An early growth stage fund specializing in deep tech startups, focused on assisting companies with competitive products in scaling their operations within the international market.
BGF
BGF is a prominent independent investor in the United Kingdom, providing growth capital to small and mid-sized businesses across diverse sectors and regions.
What's next for Abselion?
With the successful closure of this Series A round, Abselion is poised to shift its operational focus toward global commercialization and product iteration. The strategic roadmap likely includes scaling the manufacturing of the Amperia system to meet anticipated demand and expanding its sales footprint across international markets. Furthermore, the company is expected to leverage its recent capital to deepen its R&D capabilities, potentially exploring new applications for its core technology in proteomics and drug discovery. As Abselion matures, the focus will remain on maintaining its competitive edge in laboratory automation while fostering strategic partnerships that integrate its technology into broader bioprocessing workflows.
See full Abselion company page
